[Cancer Immunotherapy Utilizing T Cell Receptor Gene Engineering].
Immune-checkpoint inhibitors have shown their efficacy in the treatment of patients with many kinds of progressive/relapsed cancers. However, the efficacy remains as 10-40%of the patients in most type of cancers, suggesting that the development of new therapy for patients resistant to the therapy is an urgent unmet need. Adoptive therapy with tumor-specific T cells is a promising therapy that can be effective in patients who are not benefited from the immune-checkpoint inhibitors. The T cell therapy with genetic engineering in T cell receptor(TCR)is expected to be a universal therapy because this therapy can be applicable for patients with many kinds of cancers. This review outlines the recent clinical development of cancer immunotherapy utilizing TCR-gene engineered T cells and discusses the issues that should be improved in the near future for the safer and more effective TCR-T cell therapy of the broad range of cancer patients.